Skip to main content
Premium Trial:

Request an Annual Quote

Benitec to Collaborate with Stanford University on Pain Drug

Premium

Benitec Biopharma this week said that it is collaborating with Stanford University to test its expressed RNAi-based neuropathic pain treatment, called Nervarna, in vivo.

Nervarna is designed to inhibit protein kinase C gamma, which plays a role in various cellular signaling pathways. Benitec aims to initially develop the drug for use in terminally ill cancer patients.

Through the newly announced collaboration, Stanford researcher David Yeomans will test the agent in a spared-nerve injury model. Benitec CEO Peter French said in a statement that data generated from the experiments, if positive, will lay the groundwork for clinical testing of Nervarna in 2013.

This timeline represents an improvement from previous company guidance, provided in June, putting the drug on track to enter human testing in early 2014 (GSN 6/21/2012).

French added that the data are also expected to support Benitec's efforts to secure a pharmaceutical industry partner for the pain program.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.